1-9 of 9
Olivier Elemento
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms

Available to Purchase
Haocheng Yu, John P. Sfakianos, Li Wang, Yang Hu, Jorge Daza, Matthew D. Galsky, Harkirat S. Sandhu, Olivier Elemento, Bishoy M. Faltas, Adam M. Farkas, Nina Bhardwaj, Jun Zhu, David J. Mulholland
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (11): 1729–1741.
https://doi.org/10.1158/1535-7163.MCT-22-0130
Published: 03 November 2022
View articletitled, Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms
Open the PDF for Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms in another window
Includes: Supplementary data
Journal Articles

SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

Available to Purchase
Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa, Himisha Beltran
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (5): 1157–1164.
https://doi.org/10.1158/1535-7163.MCT-19-0926
Published: 04 May 2020
View articletitled, SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Open the PDF for SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract CN06-01: Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer

Free
Himisha Beltran, Sheng-Yu Ku, Vincenza Conteduca, Alessandro Romanel, Loredana Puca, Michael Sigouros, Juan Miguel Mosquera, Scott T. Tagawa, Andrea Sboner, Olivier Elemento, David Goodrich, David Rickman, Amina Zoubeidi, Francesca Demichelis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): CN06-01.
https://doi.org/10.1158/1535-7163.TARG-19-CN06-01
Published: 01 December 2019
View articletitled, Abstract CN06-01: Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer
Journal Articles

Abstract B031: OneThree Biotech’s artificial intelligence platform for optimizing drug development

Free
Coryandar Gilvary, Neel Madhukar, Olivier Elemento
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B031.
https://doi.org/10.1158/1535-7163.TARG-19-B031
Published: 01 December 2019
View articletitled, Abstract B031: OneThree Biotech’s artificial intelligence platform for optimizing drug development
Journal Articles

Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology

Free
Neel S. Madhukar, Varun Vijay Prabhu, Lakshmi Anantharaman, Chidananda Sulli, Edgar Davidson, Sean Deacon, Joseph Rucker, Neil Charter, Benjamin Doranz, Wolfgang Oster, Olivier Elemento, R. Benjamin Free, David Sibley, Joshua E. Allen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B130.
https://doi.org/10.1158/1535-7163.TARG-17-B130
Published: 01 January 2018
View articletitled, Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology
Journal Articles

Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses

Free
Varun Vijay Prabhu, Neel Madhukar, C. Leah B. Kline, Rohinton Tarapore, Wafik El-Deiry, Olivier Elemento, Faye Doherty, Alexander VanEngelenburg, Jessica Durrant, Andrew Zloza, Cyril Benes, Isabel Arrillaga, Wolfgang Oster, Joshua E. Allen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A060.
https://doi.org/10.1158/1535-7163.TARG-17-A060
Published: 01 January 2018
View articletitled, Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses
Journal Articles

Abstract B142: A “moneyball” approach to predicting clinical trial failures and successes

Free
Kaitlyn Gayvert, Neel Madhukar, Olivier Elemento
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B142.
https://doi.org/10.1158/1535-7163.TARG-15-B142
Published: 01 December 2015
View articletitled, Abstract B142: A “moneyball” approach to predicting clinical trial failures and successes
Journal Articles

Abstract B162: Small molecule target prediction and identification of novel anti-cancer compounds using a data-driven bayesian approach

Free
Neel S. Madhukar, Linda Huang, Prashant Khade, Katie Gayvert, Paraskevi Giannakakou, Olivier Elemento
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B162.
https://doi.org/10.1158/1535-7163.TARG-15-B162
Published: 01 December 2015
View articletitled, Abstract B162: Small molecule target prediction and identification of novel anti-cancer compounds using a data-driven bayesian approach
Journal Articles

Abstract C112: Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity

Free
Akash Patnaik, Kenneth Swanson, Sabina Signoretti, Huihui Ye, Eva Csizmadia, Jesse Novak, Marina Gehring, Katja Helenius, Athalia Pyzer, Laleh Montaser, Lily Wang, Olivier Elemento, Elena Levantini, John Clohessy, John Asara, Kathleen Kelly, Pier Paolo Pandolfi, Jacalyn Rosenblatt, David Avigan, Steven Balk, Lewis Cantley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C112.
https://doi.org/10.1158/1535-7163.TARG-15-C112
Published: 01 December 2015
View articletitled, Abstract C112: Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity